Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide

Chang Jer Wu, Jia Tsrong Jan, Chi Min Chen, Hsing Pang Hsieh, Der Ren Hwang, Hwan Wun Liu, Chiu Yi Liu, Hui Wen Huang, Su Chin Chen, Cheng Fong Hong, Ren Kuo Lin, Yu Sheng Chao, John T.A. Hsu

Research output: Contribution to journalArticlepeer-review

177 Citations (Scopus)


Antiviral agents are urgently needed to fight severe acute respiratory syndrome (SARS). We showed that niclosamide, an existing antihelminthic drug, was able to inhibit replication of a newly discovered coronavirus, SARS-CoV; viral antigen synthesis was totally abolished at a niclosamide concentration of 1.56 μM, as revealed by immunoblot analysis. Thus, niclosamide represents a promising drug candidate for the effective treatment of SARS-CoV infection.

Original languageEnglish
Pages (from-to)2693-2696
Number of pages4
JournalAntimicrobial agents and chemotherapy
Issue number7
Publication statusPublished - 2004 Jul

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide'. Together they form a unique fingerprint.

Cite this